Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.
Journal: The Journal of infectious diseases
Published: October 19, 2023
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants.
Journal: Clinical and translational science
Published: April 13, 2023
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study.
Journal: Infectious diseases and therapy
Published: December 09, 2022
Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.
Journal: Clinical and translational science
Published: September 09, 2022
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Journal: Molecules (Basel, Switzerland)
Published: June 05, 2022
Outpatient Remdesivir to Prevent Progression to Severe Covid-19. Reply.
Journal: The New England journal of medicine
Published: February 16, 2022
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Journal: The New England journal of medicine
Published: December 22, 2021
Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?"
Journal: Antimicrobial agents and chemotherapy
Published: February 09, 2021
Late-Onset T1DM and Older Age Predict Risk of Additional Autoimmune Disease.
Journal: Diabetes care
Published: May 26, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026